Champions Oncology (CSBR) Cash from Investing Activities (2010 - 2026)
Champions Oncology's (CSBR) quarterly Cash from Investing Activities came in at -$55000.0 in Q3 2026, down 19.57% year-over-year from -$68378.4 in Q3 2025, and up 76.89% on a QoQ basis from -$238000.0 in Q2 2026.
Powered by 
Analysis
Champions Oncology (CSBR) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Champions Oncology (CSBR) has 17 years of Cash from Investing Activities data on file, last reported at -$55000.0 in Q3 2026.
- On a quarterly basis, Cash from Investing Activities fell 19.57% year-over-year to -$55000.0 in Q3 2026; TTM through Jul 2026 was -$549000.0, a 26.21% decrease from a year earlier, with the FY2026 full-year figure at -$540000.0, down 38.82% from the prior year.
- Cash from Investing Activities for Q3 2026 stood at -$55000.0, up from -$238000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $3000.0 in Q2 2024 and bottomed at -$760000.0 in Q2 2023.
- Historically, Cash from Investing Activities has averaged -$311277.8 across 5 years, with a median of -$240000.0 in 2025.
- The widest annual swing landed in 2024, when Cash from Investing Activities jumped 100.39%; it then plunged 8533.33% in 2025.
- Year by year, Cash from Investing Activities stood at -$604000.0 in 2022, then surged by 86.92% to -$79000.0 in 2023, then declined by 18.99% to -$94000.0 in 2024, then plunged by 157.45% to -$242000.0 in 2025, then jumped by 77.27% to -$55000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$55000.0 in Q3 2026, -$238000.0 in Q2 2026, and -$14000.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | -381.00 Mn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | -23.89 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | -108.34 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | 28.10 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | -7.00 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | 11.09 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | -55,000.00 |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | -55,941.69 |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | -23,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 31, 2026 | -55,000.00 |
| Apr 30, 2026 | -238,000.00 |
| Jan 31, 2026 | -14,000.00 |
| Oct 31, 2025 | -242,000.00 |
| Jul 31, 2025 | -46,000.00 |
| Apr 30, 2025 | -253,000.00 |
| Jan 31, 2025 | -42,000.00 |
| Oct 31, 2024 | -94,000.00 |
| Apr 30, 2024 | 3,000.00 |
| Jan 31, 2024 | -92,000.00 |
| Oct 31, 2023 | -79,000.00 |
| Jul 31, 2023 | -668,000.00 |
| Apr 30, 2023 | -760,000.00 |
| Jan 31, 2023 | -754,000.00 |
| Oct 31, 2022 | -604,000.00 |
| Jul 31, 2022 | -754,000.00 |
| Apr 30, 2022 | -506,000.00 |
| Jan 31, 2022 | -405,000.00 |
| Oct 31, 2021 | -566,000.00 |
| Jul 31, 2021 | -907,000.00 |